Evidence map›Paper›PMID 18634022›Full record

ArticleHuman mutation2009

Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.

M Mitui, S A Nahas, L T Du, Z Yang, C H Lai, K Nakamura, S Arroyo, S Scott, A Purayidom, P Concannon and 2 more

Open access · greenAbstract read
In one paragraph

Article in Human mutation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Polymorphism rs1801516 (G > A) in theThe Journal of international medical research · 2020
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Missense Mutations inAnimals : an open access journal from MDPI · 2025
    Article
  7. Article
  8. Article
  9. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. BeyondJournal of clinical medicine · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

M MituiDepartment of Pathology and Laboratory Medicine, The David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California 90095-1732, USA.
S A Nahas
L T Du
Z Yang
C H Lai
K Nakamura
S Arroyo
S Scott
A Purayidom
P Concannon
M Lavin
R A Gatti
University of California, Los Angeles · USUniversity of Queensland · AUUniversity of Virginia · USWashington University in St. Louis · US

Funding

UCLA Center for Biological RadioprotectorsU19AI067769 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCBRIDE, WILLIAM H. · 2005 to 2019
$44.6M
PRECLINICAL STUDIES OF ATAXIA-TELANGIECTASIAR01NS035322 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GATTI, RICHARD A · 1998 to 2005
$2.1M
DRUG-INDUCED ATM READTHROUGH OF PTC MUTATIONSR01NS052528 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GATTI, RICHARD A · 2007 to 2011
$1.8M
NIAID NIH HHS AI067769NIAID NIH HHS U19 AI067769NINDS NIH HHS NS052528NINDS NIH HHS NS35322NINDS NIH HHS R01 NS035322NINDS NIH HHS R01 NS052528
6 · The paper itself

Abstract

The functional consequences of missense variants are often difficult to predict. This becomes especially relevant when DNA sequence changes are used to determine a diagnosis or prognosis. To analyze the consequences of 12 missense variants in patients with mild forms of ataxia-telangiectasia (A-T), we employed site-directed mutagenesis of ataxia-telangiectasia mutated (ATM) cDNA followed by stable transfections into a single A-T cell line to isolate the effects of each allele on the cellular phenotype. After induction of the transfected cells with CdCl2, we monitored for successful ATM transcription and subsequently assessed: 1) intracellular ATM protein levels; 2) ionizing radiation (IR)-induced ATM kinase activity; and 3) cellular radiosensitivity. We then calculated SIFT and PolyPhen scores for the missense changes. Nine variants produced little or no correction of the A-T cellular phenotype and were interpreted to be ATM mutations; SIFT/PolyPhen scores supported this. Three variants corrected the cellular phenotype, suggesting that they represented benign variants or polymorphisms. SIFT and PolyPhen scores supported the functional analyses for one of these variants (c.1709T>C); the other two were predicted to be "not tolerated" (c.6188G>A and c.6325T>G) and were classified as "operationally neutral." Genotype/phenotype relationships were compared: three deleterious missense variants were associated with an increased risk of cancer (c.6679C>T, c.7271T>G, and c.8494C>T). In situ mutagenesis represents an effective experimental approach for distinguishing deleterious missense mutations from benign or operationally neutral missense variants.

Indexed as

Mutation, MissenseAtaxia TelangiectasiaAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsComputational BiologyDNA-Binding ProteinsGenetic Predisposition to DiseaseGenetic VariationGenotypeHumansMutagenesis, Site-DirectedNeoplasmsPhenotypeProtein Serine-Threonine KinasesRisk FactorsTransfectionAtaxia Telangiectasia Mutated ProteinsATM protein, humanCell Cycle ProteinsDNA-Binding ProteinsProtein Serine-Threonine KinasesTumor Suppressor Proteins

Identifiers

PMID18634022
PMCPMC2776735
OpenAlexW2117146961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.